US Markets for Clot Management Devices 2009

The clot management device market will be predominantly driven by product innovations that result in more efficient treatment times, reduced complications, and better patient outcomes in the treatment of vascular thrombosis. In addition, the growing interest in the endovascular treatment of relatively underpenetrated diseases, such as deep vein thrombosis and acute ischemic stroke, will drive further procedure expansion. Device adoption will be largely affected by the lack of long-term clinical data definitively demonstrating the beneficial effects of clot management procedures on patient outcomes when compared to alternative therapies. Furthermore, device complications and limited physician training and experience will cause device adoption to be conservative for most of the forecast period.

Report Highlights:

• Analyze clot management device usage, at the indication level, for arteriovenous, peripheral artery, venous, pulmonary embolism, coronary, and neurovascular indications.
• Understand how the lack of long-term clinical data will impede adoption of clot management technology over the forecast period.
• Assess how drug-device combination therapies, such as pharmacomechanical thrombectomy, will impact clot management procedures through 2013.